NasdaqGS:TXGLife Sciences
10x Genomics (TXG) Is Down 5.4% After Shelf Offer Filing And Cautious 2026 Outlook What's Changed
In February 2026, 10x Genomics reported fourth-quarter 2025 revenue of US$166.03 million with a reduced net loss of US$16.25 million, and filed a US$138.83 million shelf registration for 7,661,479 Class A shares tied to an employee stock plan.
Alongside improved full-year 2025 loss metrics and cautious 2026 revenue guidance, 10x Genomics deepened its role in AI-driven cancer research through the PharosAI collaboration using its Xenium spatial platform.
Next, we’ll assess how stronger cost...